Skip to main content

View full-text article in PMC

. 2018 Feb 26;8(1):2. doi: 10.1051/bmdcn/2018080102

Table 2.

The relationship between the presence of integrons and resistance to antibiotics in clinical isolates of Pseudomonas aeruginosa in the present study.

	All isolates (n = 200)			Integron positives (n = 55)			Integron negatives (n = 145)


Antibiotics	R^*	I^*	S^*	R^*	I^*	S^*	R^*	I^*	S^*	P value^**
Antibiotics	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	P value^**
Amikacin	110	9	81	34	2	19	79	3	63	NS^*
Amikacin	(55)	(4.5)	(40.5)	(61.8)	(3.6)	(34.5)	(54.4)	(2)	(43.4)	NS^*
Cefepime	125	0	75	36	0	19	89	0	56	NS
Cefepime	(62.5)	0	(37.5)	(65.4)	0	(34.5)	(61.3)	0	(38.6)	NS
Ceftazidime	113	0	67	40	0	15	93	0	52	NS
Ceftazidime	(66.5)	0	(33.5)	(72.7)	0	(27.2)	(64.1)	0	(33.8)	NS
Tobramycin	115	0	85	26	0	29	86	0	59	NS
Tobramycin	(57.5)	0	(42.5)	(47.2)	0	(52.7)	(59.3)	0	(40.6)	NS
Gentamicin	124	0	76	39	0	16	85	0	60	NS
Gentamicin	(62)	0	(38)	(70.9)	0	(29)	(58.9)	0	(41.3)	NS
Imipenem	93	12	95	25	3	17	73	5	67	NS
Imipenem	(46.5)	(6)	(47.5)	(45.4)	(5.4)	(30.9)	(50.3)	(3.4)	(46.2)	NS
Colistin	6	0	194	2	0	53	4	0	141	NS
Colistin	(3)	0	(97)	(3.6)	0	(96.3)	(2.7)	0	(97.2)	NS
Ciprofloxacin	125	0	75	33	0	22	88	0	57	NS
Ciprofloxacin	(62.5)	0	(37.5)	(60)	0	(40)	(60.6)	0	(39.3)	NS
Amoxicillinclavulanate	121	0	79	33	0	22	86	0	59	NS
Amoxicillinclavulanate	(60.5)	0	(39.5)	(60)	0	(40)	(59.3)	0	(40.6)	NS
Cefotaxime	149	3	48	39	1	15	109	2	34	NS
Cefotaxime	(74.5)	(1.5)	(24)	(70.9)	(1.8)	(27.2)	(75.1)	(1.3)	(23.4)	NS
Ceftazidimeclavulanate	110	0	90	33	0	22	77	0	68	NS
Ceftazidimeclavulanate	(55)	0	(45)	(60)	0	(40)	(53.1)	0	(46.8)	NS

^*

R: resistant. I: intermediate. S: susceptible. NS: not statistically significant.

^**

Statistical analysis was done by Chi-square method using SPSS software. All other statistical analysis were done by descriptive methods.